| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.7 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |